Crohn's Disease, Psoriasis, Rheumatoid Arthritis, Ulcerative Colitis
Conditions
Brief summary
Coral is conducting a large study comparing and predicting the relative effectiveness of different medications for autoimmune patients. Patients with Inflammatory Bowel Disease (IBD) who have been diagnosed with either Ulcerative Colitis or Crohn's Disease and are undergoing treatment are eligible to participate. Patients with Rheumatoid Arthritis (RA) and Psoriasis (Ps) will also be enrolled. A novel clinical test will be performed to predict the responsiveness of a particular patient to different immune modulating therapies used in these conditions.
Interventions
DIAGNOSTIC_TESTCoral FRS test
A novel clinical test to predict autoimmune medication response
Sponsors
National Human Genome Research Institute (NHGRI)
Coral Genomics, Inc.
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ulcerative Colitis, Crohn's Disease, Rheumatoid Arthritis, Psoriasis diagnosis * On or about to begin a treatment for condition above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prediction of medication response | retrospective and 6 months prospectively | AUC measure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prediction of disease severity | at enrollment | R-squared measure of predicting current disease severity measure |
| Classification of disease | at enrollment | AUC measure at determining the diagnosis/disease of a patient |
Countries
United States
Outcome results
None listed